Next Article in Journal
Correction: Kim et al. The Medium Cut-Off Membrane Does Not Lower Protein-Bound Uremic Toxins. Toxins 2022, 14, 779
Next Article in Special Issue
The Bi-Functional Paxilline Enriched in Skin Secretion of Tree Frogs (Hyla japonica) Targets the KCNK18 and BKCa Channels
Previous Article in Journal
Sustainable Strategies to Counteract Mycotoxins Contamination and Cowpea Weevil in Chickpea Seeds during Post-Harvest
Previous Article in Special Issue
Exploring the Pivotal Components Influencing the Side Effects Induced by an Analgesic-Antitumor Peptide from Scorpion Venom on Human Voltage-Gated Sodium Channels 1.4 and 1.5 through Computational Simulation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 15
Issue 1
10.3390/toxins15010062
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell’s Viper (Daboia siamensis) Venom Toxicity

by
Mimi Lay
1,
Qing Liang
1,2,
Geoffrey K. Isbister
1,3 and
Wayne C. Hodgson
1,*
1
Monash Venom Group, Department of Pharmacology, Biomedical Discovery Institute, Monash University, Clayton, VIC 3800, Australia
2
Department of Emergency Medicine, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Rd, Guangzhou 510120, China
3
Clinical Toxicology Research Group, University of Newcastle, Callaghan, NSW 2308, Australia
*
Author to whom correspondence should be addressed.
Toxins 2023, 15(1), 62; https://doi.org/10.3390/toxins15010062
Submission received: 19 December 2022 / Revised: 8 January 2023 / Accepted: 9 January 2023 / Published: 11 January 2023
(This article belongs to the Special Issue Advanced Research on Animal Venoms in China)
Browse Figures
Review Reports Versions Notes

Abstract

:
The venom of the Russell’s viper (Daboia siamensis) contains neurotoxic and myotoxic phospholipase A2 toxins which can cause irreversible damage to motor nerve terminals. Due to the time delay between envenoming and antivenom administration, antivenoms may have limited efficacy against some of these venom components. Hence, there is a need for adjunct treatments to circumvent these limitations. In this study, we examined the efficacy of Chinese D. siamensis antivenom alone, and in combination with a PLA2 inhibitor, Varespladib, in reversing the in vitro neuromuscular blockade in the chick biventer cervicis nerve-muscle preparation. Pre-synaptic neurotoxicity and myotoxicity were not reversed by the addition of Chinese D. siamensis antivenom 30 or 60 min after venom (10 µg/mL). The prior addition of Varespladib prevented the neurotoxic and myotoxic activity of venom (10 µg/mL) and was also able to prevent further reductions in neuromuscular block and muscle twitches when added 60 min after venom. The addition of the combination of Varespladib and antivenom 60 min after venom failed to produce further improvements than Varespladib alone. This demonstrates that the window of time in which antivenom remains effective is relatively short compared to Varespladib and small-molecule inhibitors may be effective in abrogating some activities of Chinese D. siamensis venom.
Keywords:
neurotoxicity; myotoxicity; Russell’s viper; Daboia siamensis; Varespladib; antivenom
Key Contribution: This study provides further evidence that antivenoms are unlikely to reverse already established pre-synaptic neurotoxicity and myotoxicity caused by Chinese D. siamensis venom. Varespladib, a specific PLA2 inhibitor, can both prevent and delay in vitro PLA2-mediated pre-synaptic neurotoxicity, supporting the further use of specific toxin inhibitors against venom toxicity.

1. Introduction

The Russell’s viper (Daboia siamensis) has a vast but disjointed distribution across many regions of South and South-East Asia. It is found in parts of Pakistan, India, Bangladesh and Sri Lanka and, further east, in Taiwan, Thailand, Indonesia and Mainland China [1,2]. Across this distribution, D. siamensis is responsible for a large number of envenomings, which can result in marked local and systemic injuries in envenomed humans [3,4,5,6,7]. Although data regarding the incidence of bites in China are not available, clinical anecdotes suggest that they are relatively common. Combined with a lack of standardised and effective antivenom treatment, the overall fatality and disability rate is concerning [8]. Typically, envenoming by Daboia species is characterised by haemostatic disturbances, systemic bleeding, neurotoxicity, acute kidney injury, muscle damage, ecchymosis, swelling and pain [1,4,6,7,8,9,10,11,12,13].
Most viper venoms are dominated by three major protein families, including snake-venom metalloproteases (SVMPs), snake-venom serine proteases (SVSPs) and phospholipase A2 (PLA2) toxins [14]. Accordingly, these families represent more than 60% of all toxins found in viper venoms [14]. Of major interest are snake venom PLA2 toxins, as they have a critical role in the early morbidity and mortality of snake-bite victims. PLA2 toxins are a large family of enzymatic proteins that exert a wide variety of pharmacological and biochemical effects and have been isolated from both elapid and viperid species [15,16,17,18,19,20]. Those present in elapids are categorised within group I, whereas those found in Viperidae venoms are within group II [21,22]. Such toxins have been reported to be responsible for neurotoxicity (i.e., taipoxin from Oxyuranus scutellatus, Coastal taipan) [16,23], myotoxicity (i.e., crotoxin from Crotalus durissus terrificus, South American rattlesnake) [24,25], pain and oedema, cardiovascular disturbances, haemolysis and coagulation disorders, amongst other effects [18,26,27,28,29,30].
Proteomic studies of Daboia species have shown that the venoms contain large amounts of PLA2 that display pre-synaptic neurotoxicity, myotoxicity or cytotoxicity in different models [5,8,12,13,14,18,31]. Previous biochemically characterised pre-synaptic PLA2 toxins from Daboia species include Daboiatoxin (Myanmar), Viperitoxin F (Taiwan) and Russtoxin (Thailand) [31,32,33]. Our laboratory has previously characterised the major PLA2 toxins, i.e., U1-viperitoxin-Dr1a and U1-viperitoxin-Dr1b, from Sri Lankan Russell’s viper venom, which are postulated to be responsible for neurotoxicity and mild myotoxicity in envenomed patients [6,18]. While envenoming by Chinese D. siamensis has not been reported to produce clinically evident neurotoxicity, we have shown the venom displays pre-synaptic neurotoxicity and myotoxicity in the chick biventer cervicis nerve-muscle preparation [34]. These activities of the venoms from Daboia species have been attributed to the presence of PLA2s, both clinically and in vitro [13,15,18,32,35,36,37,38].
Antivenoms are the main treatment for systemic envenoming in humans. However, challenges remain with the use of antivenoms, including poor efficacy against some local venom effects and the presence of immunoglobulins that do not bind all toxins. In addition, the need to administer antivenoms in healthcare facilities, the risk of adverse reactions and cold-storage requirements and supply chain issues, especially in rural/remote areas where snake bites are often widespread, remain [30,39,40]. Unless given early, antivenoms are generally considered ineffective against some effects of snake-bite envenoming, given that the effectiveness of antibodies is limited by their penetrability into peripheral sites [41]. In the case of venoms containing pre-synaptic neurotoxins, neuromuscular paralysis is generally irreversible, as these toxins result in damage to the nerve terminal after exposure to venom [23,42]. As a result, treatment with antivenoms or acetylcholinesterase inhibitors often has limited effectiveness [41]. This has been reported clinically [6,43] and replicated in studies using ex vivo neuromuscular junctions [16,36,42].
The high specificity of polyclonal antibodies means that antivenoms are normally highly efficacious against the venom for which they are raised, but generally display less efficacy against snake venoms of different genera or families [44]. There is currently no specific antivenom, commercially available, for envenoming by Chinese D. siamensis. Fortunately, a species-specific monovalent antivenom has been developed, which we have shown to be efficacious in preventing in vitro neurotoxic and myotoxic effects [34]. However, studies testing the efficacy of this antivenom in reversing venom-mediated effects and examining the window of time in which antivenom remains effective are required. Given that D. siamensis venom appears to contain pre-synaptic neurotoxins and myotoxins, both of which are considered clinically and experimentally difficult to reverse, the exploration of an alternative or a complementary treatment for D. siamensis envenoming is important.
As PLA2 toxins are functionally critical and ubiquitous in many venoms, targeting this toxin class is an ideal target for treating many aspects of snake envenoming [14,19,40]. In this context, small-molecule inhibitors have been gaining attention as potential alternatives to immuno-based therapies due to their promising safety profile and general inhibitory broadness across snake species. Most notable is Varespladib (or LY315920), a PLA2 inhibitor that shows pre-clinical efficacy against a wide variety of elapid and viper venoms [44,45]. Varespladib demonstrates inhibitory activity against a variety of snake venoms and toxins, including against the ‘irreversible’ pre-synaptic neurotoxins and myotoxins [23,45,46,47]. Lewin et al. [45] demonstrated that Varespladib and methyl-Varespladib had a wide breadth of efficacy against the venoms from 28 different snake species, all with variable PLA2 activity. Additionally, the anti-pre-synaptic neurotoxic capability of Varespladib has been demonstrated against isolated toxins, such as taipoxin, in an in vitro neuromuscular preparation [23]. It has also been observed that Varespladib extends the window of time for the prevention or reversal of neuromuscular paralysis, muscle damage or venom-induced lethality in mice [23,48,49].
Given that PLA2 toxins are present in D. siamensis venom, and there is currently not a specific antivenom available for clinical use, we examined the efficacy of Varespladib to inhibit PLA2 toxicity of D. siamensis venom. We also compared the ability of Chinese D. siamensis monovalent antivenom to reverse the toxicity of Chinese D. siamensis venom alone and in combination with Varespladib.

2. Results

2.1. In Vitro Antivenom Reversal Studies

2.1.1. Effect of Chinese D. siamensis Monovalent Antivenom on Pre-Synaptic Neurotoxicity Induced by D. siamensis Venom

Chinese D. siamensis venom (10 µg/mL) in the absence of antivenom caused a reduction in indirect (nerve-mediated) twitches in the chick biventer cervicis nerve-muscle preparation, with a time to reach 50% twitch inhibition (i.e., t50 value) of 147 ± 12 min (n = 11–12, Figure 1a,b). Post-venom contractile responses to exogenous ACh, CCh or KCl were obtained to identify the site of neurotoxic activity, and were unaffected by the venom when compared to vehicle control, indicative of pre-synaptic neurotoxicity (Figure 1c).
Chinese D. siamensis antivenom (15 µL; 3x recommended concentration; [33]) added either 30 or 60 min after venom did not have a marked effect on the inhibitory action of the venom (Figure 1a,b). There was a slight reduction in twitch inhibition after 3 h when antivenom was added at the 30 min timepoint (Figure 1a). Antivenom added 30 or 60 min after venom had no significant effect on the agonist responses in the presence of venom (Figure 1c).

2.1.2. Effect of Chinese D. siamensis Monovalent Antivenom on Myotoxicity Induced by D. siamensis Venom

Chinese D. siamensis venom (10 µg/mL) caused a reduction in direct twitches in the chick biventer cervicis nerve-muscle preparation, with a time to reach 50% twitch inhibition (i.e., t50 value) of 115 ± 4 min (Figure 2a,c). Chinese D. siamensis venom (10 µg/mL) also caused an increase in resting baseline tension (Figure 2b,d), indicative of myotoxicity.
Chinese D. siamensis antivenom (20 µL; 4x recommended concentration; [33]) added either 30 or 60 min after venom did not restore twitch height (Figure 2a,c) but did cause a slight reduction in the increase in baseline tension, at both time points, although this effect was not statistically significant compared to venom in the absence of antivenom (Figure 2b,d).

2.2. Phospholipase A2 Assay

The sPLA2 activity of Chinese D. siamensis venom was 865 ± 158 µmol/min/mg. The PLA2 activity of venom was abolished by Varespladib (20 µM), i.e., undetectable when incubated with the inhibitor. Bee venom was used as a positive control and displayed an activity of 554 ± 6 µmol/min/mg.

2.3. In Vitro Protection Studies Using Varespladib

2.3.1. Effect of Varespladib on the Pre-Synaptic Neurotoxicity of D. siamensis Venom

Pre-incubation (15 min) of Chinese D. siamensis venom (10 µg/mL) with Varespladib (0.8 or 26 µM), before addition to the organ bath, prevented the effects of venom, i.e., a reduction in indirect twitches in the chick biventer cervicis nerve-muscle preparation (Figure 3a). Varespladib alone (0.8 or 26 µM) had no significant effect on twitch response or contractile responses to agonists (Figure 3a,b), although the combination of venom and Varespladib slightly potentiated contractile responses to ACh and CCh, but not KCl (Figure 3b).

2.3.2. Effect of Varespladib on the Myotoxicity of D. siamensis Venom

Chinese D. siamensis venom (10 µg/mL) caused a reduction in direct twitches in the chick biventer cervicis nerve-muscle preparation. Pre-incubation (15 min) of venom with Varespladib (0.8 or 26 µM) significantly inhibited the reduction in direct twitch height mediated by Chinese D. siamensis venom, with slightly lower neutralisation by the lower concentration of Varespladib (Figure 4a). Varespladib also abolished the increase in baseline tension when compared to venom alone, with no concentration-dependent difference between the effects of the two concentrations (Figure 4b).

2.4. In Vitro Reversal Studies by Varespladib

2.4.1. Effect of Post-Venom Addition of Varespladib on the Pre-Synaptic Neurotoxicity of D. siamensis Venom

To determine the ability of Varespladib to reverse the neurotoxic effects of Chinese D. siamensis venom, Varespladib (0.8 or 26 µM) was added 60 min after venom. Varespladib was able to partially restore the venom-mediated reduction in indirect twitches at both concentrations (Figure 5). This effect was transient, but Varespladib also prevented a further decline in twitch height.

2.4.2. Effect of Post-Venom Addition of Varespladib on the Myotoxicity of D. siamensis Venom

Varespladib (26 µM), added 60 min after Chinese D. siamensis venom, prevented a further decline in direct twitches compared to venom alone (Figure 6a). However, a lower concentration of Varespladib (0.8 µM) did not cause a statistically significant delay in direct twitch inhibition. Both concentrations of Varespladib (i.e., 0.8 and 26 µM) reversed the venom-induced increase in baseline tension (Figure 6b).

2.4.3. Effect of Post-Venom Addition of the Combination of Varespladib and Antivenom on the Pre-Synaptic Neurotoxicity of D. siamensis Venom

The combination of the lower concentration of Varespladib (0.8 µM) with Chinese D. siamensis antivenom (15 µL) prevented a further decline in twitch height when added 60 min post-venom (Figure 7). However, this effect was not significantly different from Varespladib (0.8 µM) alone, indicating no synergistic effect of the combination.

2.4.4. Effect of Post-Venom Addition of the Combination of Varespladib and Antivenom on the Myotoxicity of D. siamensis Venom

The combination of the lower concentration of Varespladib (0.8 µM) with Chinese D. siamensis antivenom (20 µL) had a small but significant effect on venom-induced twitch inhibition (Figure 8a). However, this effect was not significantly different from Varespladib (0.8 µM) alone. The combination of Varespladib (0.8 µM) and Chinese D. siamensis antivenom (20 µL) also reversed the increase in baseline tension induced by the venom, but this was not different from Varespladib (0.8 µM) alone, indicating no synergistic effect of the combination (Figure 8b).

3. Discussion

We previously reported that the in vitro pre-synaptic neurotoxic and myotoxic effects of Chinese D. siamensis venom are neutralised (i.e., prevented) by the pre-addition of specific Chinese D. siamensis monovalent antivenom, indicating the efficacy of this antivenom [34]. However, as these observations would not readily translate into clinical effectiveness, in the current study, we examined the ability of Chinese D. siamensis monovalent antivenom to prevent a further decline in and/or reverse the already established neurotoxicity and myotoxicity. We found that the antivenom was largely ineffective in preventing neuromuscular blockade when added 30 min or 60 min after venom. Additionally, the antivenom did not reverse the myotoxic effects when added at either time point. Therefore, the antivenom was unable to reverse the effects of the venom and prevent an ongoing decline in neuromuscular transmission, caused either by the action of neurotoxins (i.e., preventing neurotransmitter release) or myotoxins (i.e., damaging skeletal muscle). The limited ability of antivenoms to reverse pre-synaptic neurotoxicity and myotoxicity has been well established, both in clinical and experimental settings [6,18,23,42,43]. The lack of effectiveness of the antivenom, administered post-venom, indicates that the antibodies contained in the antivenom are unable to access the toxins, causing neuromuscular failure/damage, and/or that the effects of the ‘irreversible’ damage are likely to be occurring internally [6,19,20,36,41].
In agreement with our findings, an in vitro study on Naja naja (Indian Cobra) venom-induced muscle injury indicated a very short lag period before cytotoxins and myotoxins exerted irreversible injury, with the failure of Indian polyvalent antivenom to prevent further damage, even after 5 min [50]. The window of time in which antivenom remains effective, at least in in vitro experiments, such as these, may be very short. Indeed, we have shown that Australian polyvalent antivenom remains effective in neutralising O. scutellatus (Coastal taipan) venom or taipoxin-mediated pre-synaptic neurotoxicity only up to 10–15 min after addition of the venom/toxin [16,42]. This highlights the need for early antivenom administration for both neurotoxicity and myotoxicity, as has been described in case series where the severity of envenoming by various Australian elapids is largely reduced with antivenom administration within 2 to 6 h [51,52]. It has been suggested that local vascular alterations, i.e., haemorrhage and oedema, associated with local tissue and muscle damage, which are hallmarks of many viperid envenomings, including D. siamensis, can affect the pharmacokinetics of antivenoms. Irrespective of molecular masses of either IgG or F(ab’)2 fragments, these types of venom-induced injuries favour the extravasation of antibodies and may contribute to the difficulty in neutralising or reversing locally acting myotoxins [53,54,55]. The irreversibility of the pathophysiological effects of some toxins limits the effectiveness of antivenoms, although this is primarily due to the nature of the venoms/toxins, rather than an issue with the efficacy of the antivenoms per se [53,56]. Apart from endocytosed toxins with an intracellular site of action, toxins that target membrane-bound receptors (e.g., neurotoxins), located in the extracellular matrix (e.g., metalloproteases) or in the bloodstream (e.g., pro-coagulants), have a higher probability of binding with circulating antibodies [53]. Moreover, the mismatch between low-molecular-weight toxins and antivenom pharmaco-kinetics and -dynamics means that antivenoms are ineffective at neutralizing both locally acting toxins (e.g., myotoxins and cytotoxins) and those with an intracellular site of action [53]. This can be explained by the fact that by the time antibodies and fragments reach the site of action, significant tissue damage has occurred. Antibodies cannot cross the blood/tissue barrier, as previously mentioned, when treating local and microvascular damage, while also having reduced antibody binding and neutralisation interactions [22,41].
Immunotherapy of snake envenoming presents a difficult challenge; hence, it has been proposed that the addition of potent enzyme inhibitors may circumvent the problem of poor antivenom efficacy, especially against poorly immunogenic toxins with low molecular weight and faster absorption rate [22]. In our study, we found that pre-incubation with Varespladib prevented both the neurotoxic and myotoxic effects of D. siamensis venom, indicating the key role PLA2 toxins play in these effects. Our findings support previous reports showing that Varespladib prevents PLA2-mediated neurotoxicity and myotoxicity across a diverse range of snake venoms [23,24,25,45,47,48,57,58,59,60]. The important role of PLA2 toxins in Daboia spp. envenoming is also supported by our previous work, showing that removal of the major PLA2 toxins, i.e., U1-viperitoxin-Dr1a and U1-viperitoxin-Dr1b, from Sri-Lankan D. russelii venom resulted in a loss of in vitro neurotoxicity and myotoxicity [18,37].
Interestingly, Varespladib was also able to significantly reverse or, at least, prevent a further decline in indirect (nerve-mediated) and direct (muscle) twitches induced by venom, whereas antivenom did not display this ability. However, the administration of a combination of antivenom and Varespladib after venom addition did not result in an additive or synergistic inhibitory effect against the neurotoxic or myotoxic effects. A similar finding of greater efficacy of Varespladib over antivenom has also been reported against O. scutellatus venom, an elapid venom with PLA2-mediated neurotoxicity [23], and C. d. terrificus venom, from a viperid with PLA2-mediated neurotoxicity and myotoxicity [24,25]. These observations support in vivo experiments in mice, where Varespladib was able to inhibit the myotoxic effects of four Chinese snake venoms [44] as well as attenuate the myonecrotic and haemorrhagic activity induced by Deinagkistrodon acutus (sharp-nosed pit viper) venom [46]. In contrast, the concomitant administration of antivenom and Varespladib appeared to provide additional survival benefits following O. scutellatus [49], as well as Micrurus corallinus (Coral snake) envenoming [60] in mice and rats, respectively.
The positive effects of Varespladib raise the question of whether the morphological changes to the neuromuscular junction caused by pre-synaptic neurotoxins are, indeed, irreversible, or at least partially reversible in the time frame of the current study. The reversal studies demonstrate the inability of antivenom, both alone and in combination with Varespladib, to reverse/further prevent D. siamensis venom-mediated neurotoxicity and myotoxicity, suggesting that the antibodies are either unable to reach the target sites as efficiently as small-molecule inhibitors, have a slower onset of action or are unable to displace or bind to the antigenic site of toxins already bound to target sites [42,50,56]. Considering that the effectiveness of the treatment combination was no different to the inhibitory actions of Varespladib alone, it also indicates that the efficacy of antivenoms is limited by the bite-to-antivenom time disparity, as well as toxin–target/substrate interaction, as previously described. Furthermore, the efficacy of antivenoms also depends on a different mechanism, such as steric hindrance, by trapping the toxin in the central compartment and enhancing the efficiency for toxin removal [50,53,56].
In this regard, the higher efficacy of Varespladib over antivenoms to inhibit the activity of these toxins may be due to (1) higher potency of Varespladib to inhibit PLA2 activity at low concentrations; (2) the ability of Varespladib to bind with high affinity to neurotoxins and myotoxins, possibly displacing even those already bound extracellularly to their target sites or reducing affinity between toxin and substrate; or (3) the ability of Varespladib to enter the nerve terminal or cells, perhaps inhibiting intracellular snake venom PLA2s [20,23,24]. It is worth noting that while the progression of direct twitch inhibition induced by venom was halted, but not reversed, by Varespladib, baseline tension was restored to pre-venom levels. This suggests that changes in baseline tension are due to alterations that are not related to mechanical damage to contraction mechanisms of myofibrils.
An important limitation of our study is the extrapolation of these data into clinical settings. Considering that the inhibitory action of Varespladib is rapid but has a relatively short half-life in vivo [48], multiple dosing amounts or continuous infusion of Varespladib to maintain concentrations high enough for toxin neutralisation may be required. For future in vitro studies, repeated dosing may accommodate for the time gap between venom addition and antivenom administration, as well as the further abrogation of venom damage, mirroring a clinical situation.

4. Conclusions

Our findings suggest that while small-molecular inhibitors are unlikely to replace the use of antivenoms, Varespladib could be used for short-term, immediate treatment to delay the onset of venom toxicity and increase the window of opportunity for antivenom administration before efficacy is diminished. Our work is in line with the initiative of the World Health Organisation (WHO) to accelerate snake-bite prevention and control protocols, as well as reduce snake-bite-related cases in South-East Asia by 50% by 2030 [61].

5. Materials and Methods

5.1. Animals

5–10-day-old male brown chicks (White Leghorn crossed with New Hampshire) were used in this study and obtained from Wagner’s Poultry, Coldstream, Victoria. Animals were housed with food and water ad libitum at Monash Animal Services (Monash University, Clayton). Animal experiments were approved by the Monash University Ethics Committee (approval number 22575).

5.2. Chemicals and Drugs

The following chemicals and drugs were purchased from Sigma-Aldrich, St Louis, MO, USA: acetylcholine (ACh), carbamylcholine (CCh), d-tubocurarine (dTC), bovine serum albumin (BSA), Varespladib (CAS:172732-68-2) and dimethyl sulfoxide (DMSO). Potassium chloride (KCl) was purchased from Merck (Darmstadt, Germany). All chemicals were dissolved in MilliQ water, except Varespladib, which was dissolved in DMSO.

5.3. Venoms and Antivenoms

The Chinese Daboia siamensis venom used in this study was a pooled, freeze-dried sample from snakes collected from Yunnan province and obtained from Orientoxin Co., Ltd. (Laiyang, Shandong, China). Venom was dissolved in 0.05% (w/v) BSA to a final concentration of 2 mg/mL and frozen at −20 °C until required. Chinese D. siamensis monovalent antivenom (Batch number 20200401; expiry date: 1 April 2022) was purchased from Shanghai Serum Biological Technology Co., Ltd. (Shanghai, China). According to manufacturer’s instructions, 1 µL of Chinese D. siamensis antivenom neutralises 6 µg of D. siamensis venom. Antivenom was filtered prior to use with a 10 kDa centrifugal filter unit and centrifuged at 8000 rpm for 5 min. The supernatant was discarded and the retentate was stored at −20 °C until required. Based on the manufacturer’s neutralisation ratio the amount of antivenom was adjusted be equivalent to the concentration of unfiltered antivenom.

5.4. Isolated Chick Biventer Cervicis Nerve-Muscle Preparation

Chicks were euthanised by exsanguination following CO2 inhalation. Two biventer cervicis nerve-muscle preparations, from each chick, were dissected and suspended on wire tissue holders under 1 g resting tension in 5 mL organ baths. Tissues were bubbled with 95% O2 and 5% CO2 in physiological salt solution of the following composition: 118.4 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3 and 11.1 mM glucose, and maintained at a temperature of 34 °C.
Indirect (nerve-mediated) twitches of tissues were evoked by stimulating the motor nerve (0.1 Hz, 0.2 ms) at supramaximal voltage (10–20 V) using an LE series stimulator (ADInstruments, Pty Ltd., Bella Vista, Australia). Twitches were measured and recorded on a PowerLab system (ADInstruments, Pty Ltd., Bella Vista, Australia) via a Grass FT03 force-displacement transducer. The abolishment of twitches following addition of dTC (10 µM) ensured selective stimulation of the motor nerve. The twitches were restored to baseline levels by repeated washing of the preparation with physiological salt solution over the course of 20 min. Following this period, electrical stimulation was ceased and the tissue was allowed to rest for approximately 5 min. Contractile responses to exogenous ACh (1 mM for 30 s), CCh (20 µM for 60 s) and KCl (40 mM, 30 s) were then obtained. Electrical stimulation was then recommenced for 20–30 min or until twitches were stable. For experiments examining myotoxicity, the electrode was placed around the muscle, which was directly stimulated (0.1 Hz, 2 ms) at supramaximal voltage (20–30 V). Residual nerve-mediated responses were abolished by the addition of dTC (10 µM), which remained in the organ bath throughout the experiment. All preparations were stabilised for at least 20–30 min before commencement of the experiment.

5.5. Protection and Reversal Protocols

The neutralising ability of Varespladib was tested by either (1) pre-incubation of venom with Varespladib for 15 min prior to addition of the mixture to the organ bath or (2) by the addition of Varespladib 60 min after venom. The concentration and ratio of Varespladib used in this study was adapted from the protocol described in a previous study, Maciel et al. [25]. To determine the ability of antivenom to reverse venom-induced neurotoxicity or myotoxicity, antivenom was added to the organ bath 30 or 60 min after venom addition. Antivenom was used at 3× the recommended concentration for neurotoxicity experiments and 4× the recommended concentration for myotoxicity experiments based on our previous study where these concentrations were shown to almost abolish neurotoxicity/myotoxicity when added prior to the venom [33].

5.6. Phospholipase A2 Activity

PLA2 activity of D. siamensis venom was determined using a PLA2 assay kit (Cayman Chemical, Ann Arbour, MI, USA) according to the manufacturer’s instructions. Venom stock solution (1 mg/mL) was serially diluted to a final concentration of 7.8 µg/mL, and a pre-mixed solution containing Varespladib (20 µM), assay buffer and indicator DTNB [5,5′-dithio-bis-(2-nitrobenzoic acid)], was added to wells of a 96-well plate. Substrate solution diheptanoyl thio-PC was added to each well, and the plate was read every 2 min at a wavelength of 414 nm for 22 min. Absorbance values were measured to calculate PLA2 activity, expressed as micromoles of phosphatidylcholine hydrolysed per min per mg of enzyme (µmol/min/mg) of each venom dilution sample, and values indicated are the mean of triplicate wells. Bee venom PLA2 was used as a positive control. Varespladib concentration was chosen based on the neutralisation capabilities demonstrated in previous studies [45].

5.7. Data Analysis and Statistics

For chick biventer experiments, twitch height was measured every four minutes after venom addition and expressed as a percentage of the pre-venom twitch response. For neurotoxicity experiments, post-venom contractile responses to exogenous agonists ACh, CCh and KCl were expressed as a percentage of the corresponding pre-venom contractile response. For myotoxicity experiments, changes in baseline tension, were measured every 10 min after venom addition. Either one-way or two-way analysis of variance (ANOVA) was performed for comparisons between different treatments. Comparisons of responses to exogenous agonists before and after venom treatment were performed using a student’s paired t-test. All ANOVAs were followed by Bonferroni’s multiple comparison or Tukey’s post hoc test, respectively. Data are presented as the mean ± standard error of mean (SEM) where n is the number of tissue preparations. All data and statistical analyses were performed using Prism 9.4.1 (GraphPad Software, San Diego, CA, USA, 2022). p < 0.05 was considered statistically significant for all analyses.

Author Contributions

Conceptualization, M.L., Q.L., G.K.I. and W.C.H.; methodology, M.L., Q.L., G.K.I. and W.C.H.; formal analysis, M.L. and W.C.H.; investigation, M.L.; data curation and writing—original draft preparation, M.L.; writing—review and editing and supervision, Q.L., G.K.I. and W.C.H.; funding acquisition, Q.L., G.K.I. and W.C.H.; project administration, G.K.I. and W.C.H. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by an Australian National Health and Medical Research Council (NHMRC) Senior Research Fellowship (ID: 1154503) awarded to G.K.I., a NHMRC Centres for Research Excellence Grant (ID:1110343) awarded to G.K.I. and W.C.H., a 2021 Guangzhou Science and Technology Program City and University (Hospital) joint funded Grant (ID: 202102010282) and a 2022 General project Grant of Natural Science Foundation of Guangdong basic and applied basic research foundation (ID:2022A1515012095) awarded to Q.L.

Institutional Review Board Statement

This study was conducted according to the NHMRC Australian Code for the Care and Use of Animals for Scientific Purposes and approved by the Monash University Animal Ethics Committee. Animal ethics number: 22575. Approval date: December 2019.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Wüster, W. The genus Daboia (Serpentes: Viperidae): Russell’s Viper. Hamadryad 1998, 23, 33–40. [Google Scholar]
  2. Thorpe, R.S.; Pook, C.E.; Malhotra, A. Phylogeography of the Russell’s viper (Daboia russelii) complex in relation to variation in the colour pattern and symptoms of envenoming. Herpetol. J. 2007, 17, 209–217. [Google Scholar]
  3. Chaisakul, J.; Alsolaiss, J.; Charoenpitakchai, M.; Wiwatwarayos, K.; Sookprasert, N.; Harrison, R.A.; Chaiyabutr, N.; Chanhome, L.; Tan, C.H.; Casewell, N.R. Evaluation of the geographical utility of Eastern Russell’s viper (Daboia siamensis) antivenom from Thailand and an assessment of its protective effects against venom-induced nephrotoxicity. PLoS Negl. Trop. Dis. 2019, 13, e0007338. [Google Scholar] [CrossRef] [Green Version]
  4. Hung, D.Z.; Wu, M.L.; Deng, J.F.; Lin-Shiau, S.Y. Russell’s viper snakebite in Taiwan: Differences from other Asian countries. Toxicon 2002, 40, 1291–1298. [Google Scholar] [CrossRef]
  5. Risch, M.; Georgieva, D.; von Bergen, M.; Jehmlich, N.; Genov, N.; Arni, R.K.; Betzel, C. Snake venomics of the Siamese Russell’s viper (Daboia russelli siamensis)—Relation to pharmacological activities. J. Proteom. 2009, 72, 256–269. [Google Scholar] [CrossRef]
  6. Silva, A.; Maduwage, K.; Sedgwick, M.; Pilapitiya, S.; Weerawansa, P.; Dahanayaka, N.J.; Buckley, N.A.; Siribaddana, S.; Isbister, G.K. Neurotoxicity in Russell’s viper (Daboia russelii) envenoming in Sri Lanka: A clinical and neurophysiological study. Clin. Toxicol. 2016, 54, 411–419. [Google Scholar] [CrossRef]
  7. Warrell, D.A. Snake venoms in science and clinical medicine* 1. Russell’s viper: Biology, venom and treatment of bites. Trans. R. Soc. Trop. Med. Hyg. 1989, 83, 732–740. [Google Scholar] [CrossRef]
  8. Experts Group of Snake-bites Rescue and Treatment Consensus in China Expert Consensus on China Snake-bites rescue and Treatment. Chin. J. Emerg. Med. 2018, 27, 1315–1322. [CrossRef]
  9. Belt, P.J.; Malhotra, A.; Thorpe, R.S.; Warrell, D.A.; Wüster, W. Russell’s viper in Indonesia: Snakebite and systematics. Symp. Zool. Soc. Lond. 1997, 70, 219–234. [Google Scholar]
  10. Phillips, R.E.; Theakston, R.D.G.; Warrell, D.A.; Galigedara, Y.; Abeysekera, D.T.D.J.; Dissanayaka, P.; Hutton, R.A.; Aloysius, D.J. Paralysis, Rhabdomyolysis and Haemolysis Caused by Bites of Russell’s Viper (Vipera russelli pulchella) in Sri Lanka: Failure of Indian (Haffkine) Antivenom. Q. J. Med. 1988, 68, 691–716. [Google Scholar]
  11. Pochanugool, C.; Wilde, H.; Bhanganada, K.; Chanhome, L.; Cox, M.J.; Chaiyabutr, N.; Sitprija, V. Venomous snakebite in Thailand II: Clinical Experience. Mil. Med. 1998, 163, 318–323. [Google Scholar] [CrossRef]
  12. Tan, K.Y.; Tan, N.H.; Tan, C.H. Venom proteomics and antivenom neutralization for the Chinese eastern Russell’s viper, Daboia siamensis from Guangxi and Taiwan. Sci. Rep. 2018, 8, 8545. [Google Scholar] [CrossRef] [Green Version]
  13. Tan, N.H.; Fung, S.Y.; Tan, K.Y.; Yap, M.K.K.; Gnanathasan, C.A.; Tan, C.H. Functional venomics of the Sri Lankan Russell’s viper (Daboia russelii) and its toxinological correlations. J. Proteom. 2015, 128, 403–423. [Google Scholar] [CrossRef]
  14. Tasoulis, T.; Isbister, G.K. A Review and Database of Snake Venom Proteomes. Toxins 2017, 9, 290. [Google Scholar] [CrossRef]
  15. Chaisukal, J.; Khow, O.; Wiwatwarayos, K.; Rusmili, M.R.A.; Prasert, W.; Othman, I.; Abidin, S.A.Z.; Charoenpitakchai, M.; Hodgson, W.C.; Chanhome, L.; et al. A Biochemical and Pharmacological Characterization of Phospholipase A2 and Metalloproteinase Fractions from Eastern Russell’s Viper (Daboia siamensis) Venom: Two Major Components Associated with Acute Kidney Injury. Toxins 2021, 13, 521. [Google Scholar] [CrossRef]
  16. Herrera, M.; Collaço, R.d.C.d.O.; Villalta, M.; Segura, Á.; Vargas, M.; Wright, C.E.; Paiva, O.K.; Matainaho, T.; Jensen, S.D.; León, G.; et al. Neutralization of the neuromuscular inhibition of venom and taipoxin from the taipan (Oxyuranus scutellatus) by F(ab’)2 and whole IgG antivenoms. Toxicol. Lett. 2016, 241, 175–183. [Google Scholar] [CrossRef]
  17. Angulo, Y.; Lomonte, B. Differential susceptibility of C2C12 myoblasts and myotubes to group II phospholipases A2 myotoxins from crotalid snake venoms. Cell Biochem. Funct. 2005, 23, 307–313. [Google Scholar] [CrossRef]
  18. Silva, A.; Kuruppu, S.; Othman, I.; Goode, R.J.; Hodgson, W.C.; Isbister, G.K. Neurotoxicity in Sri Lankan Russell’s Viper (Daboia russelii) Envenoming is Primarily due to U1-viperitoxin-Dr1a, a Pre-Synaptic Neurotoxin. Neurotox. Res. 2017, 31, 11–19. [Google Scholar] [CrossRef]
  19. Gutiérrez, J.M.; Lomonte, B. Phospholipase A2: Unveiling the secrets of a functionally versatile group of snake venom toxins. Toxicon 2013, 62, 27–39. [Google Scholar] [CrossRef]
  20. Šribar, J.; Oberčkal, J.; Križaj, I. Understanding the molecular mechanisms underlying the presynaptic toxicity of secreted phospholipases A2: An update. Toxicon 2014, 89, 9–16. [Google Scholar] [CrossRef]
  21. Lomonte, B.; Gutiérrez, J.M. Phospholipases A2 From Viperidae Snake Venoms: How do They Induce Skeletal Muscle Damage. Acta Chim. Slov. 2011, 58, 647–659. [Google Scholar] [PubMed]
  22. Gutiérrez, J.M.; Ownby, C.L. Skeletal muscle degeneration induced by venom phospholipases A2: Insights into the mechanisms of local and systemic myotoxicity. Toxicon 2003, 42, 915–931. [Google Scholar] [CrossRef] [PubMed]
  23. Oliveira, I.C.F.; Gutiérrez, J.M.; Lewin, M.R.; Oshima-Franco, Y. Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in nerve-muscle preparation. Toxicon 2020, 187, 101–104. [Google Scholar] [CrossRef] [PubMed]
  24. de Souza, J.; Fontana Oliveria, I.C.F.; Yoshida, E.H.; Cantuaria, N.M.; Cogo, J.C.; Torres-Bonilla, K.A.; Hyslop, S.; Silva, N.J., Jr.; Floriano, R.S.; Gutiérrez, J.M.; et al. Effect of the phospholipase A2 inhibitor Varespladib and its synergism with crotalic antivenom, on the neuromuscular blockade induced by Crotalus durissus terrificus venom (with and without crotamine) in mouse neuromuscular preparations. Toxicon 2022, 214, 54–61. [Google Scholar] [CrossRef]
  25. Maciel, F.V.; Pinto, E.K.R.; Souza, N.M.V.; Gonçalves de Abreu, T.A.; Ortolani, P.L.; Fortes-Dias, C.L.; Calvalcante, W.L.G. Varespladib (LY315920) prevents neuromuscular blockage and myotoxicity induced by crotoxin on mouse neuromuscular preparations. Toxicon 2021, 202, 40–45. [Google Scholar] [CrossRef]
  26. Bittenbinder, M.A.; Zdenek, C.N.; Op den Brouw, B.; Youngman, N.J.; Dobson, J.S.; Naude, A.; Vonk, F.J.; Fry, B.G. Coagulotoxic cobras: Clinical implications of strong anticoagulant actions of African spitting Naja venoms that are not neutralised by antivenom but are by LY315920 (Varespladib). Toxins 2018, 10, 516. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Youngman, N.J.; Walker, A.; Naude, A.; Coster, K.; Sundman, E.; Fry, B.G. Varespladib (LY315920) neutralises phospholipase A2 mediated prothrombinase-inhibition induced by Bitis snake venoms. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2020, 236, 108818. [Google Scholar] [CrossRef]
  28. Kini, R.M. Excitement ahead: Structure, function and mechanism of snake venom phospholipase A2 enzymes. Toxicon 2003, 42, 827–840. [Google Scholar] [CrossRef]
  29. Kini, R.M.; Evans, H.J. A model to explain the pharmacological effects of snake venom phospholipases A2. Toxicon 1989, 27, 613–635. [Google Scholar] [CrossRef]
  30. Albulescu, L.O.; Xie, C.; Ainsworth, S.; Alsolaiss, J.; Crittenden, E.; Dawson, C.A.; Softley, R.; Bartlett, K.E.; Harrison, R.A.; Kool, J.; et al. A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite. Nat. Commun. 2020, 11, 6094. [Google Scholar] [CrossRef]
  31. Sanz, L.; Quesada-Bernat, S.; Chen, P.Y.; Lee, C.D.; Chiang, J.R.; Calvete, J.J. Translational Venomics: Third-Generation Antivenomics of Anti-Siamese Russell’s Viper, Daboia siamensis, Antivenom Manufactured in Taiwan CDC’s Vaccine Center. Trop. Med. Infect. Dis. 2018, 3, 66. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Maung-Maung-Thwin; Gopalakrishnakone, P.; Yuen, R.; Tan, C.H. A Major Lethal factor of the Venom of Burmese Russell’s Viper (Daboia russelli siamensis): Isolation, N-Terminal sequencing and biological activities of daboiatoxin. Toxicon 1995, 33, 63–76. [Google Scholar] [CrossRef] [PubMed]
  33. Tsai, I.H.; Lu, P.J.; Su, J.C. Two types of Russell’s viper revealed by variation in Phospholipases A2 from venom of the subspecies. Toxicon 1996, 34, 99–109. [Google Scholar] [CrossRef]
  34. Lay, M.; Liang, Q.; Isbister, G.K.; Hodgson, W.C. In Vitro Toxicity of Chinese Russell’s Viper (Daboia siamensis) Venom and Neutralisation by Antivenoms. Toxins 2022, 14, 505. [Google Scholar] [CrossRef] [PubMed]
  35. Gopalan, G.; Maung-Maung-Thwin; Gopalakrishnakone, P.; Swaminathan, K. Structural and pharmacological comparison of daboiatoxin from Daboia russelli siamensis with viperotoxin F and vipoxin from other vipers. Acta Crystallogr. Sect. D 2007, 63, 722–729. [Google Scholar] [CrossRef]
  36. Thakshila, P.; Hodgson, W.C.; Isbister, G.K.; Silva, A. In Vitro Neutralization of the Myotoxicity of Australian Mulga Snake (Pseudechis australis) and Sri Lankan Russell’s Viper (Daboia russelii) Venoms by Australian and Indian Polyvalent Antivenoms. Toxins 2022, 14, 302. [Google Scholar] [CrossRef]
  37. Silva, A.; Johnston, C.; Kuruppu, S.; Kneisz, D.; Maduwage, K.; Kleifeld, O.; Smith, A.I.; Siribaddana, S.; Buckley, N.A.; Hodgson, W.C.; et al. Clinical and Pharmacological Investigation of Myotoxicity in Sri Lankan Russell’s Viper (Daboia russelii) Envenoming. PLoS Negl. Trop. Dis. 2016, 10, e0005172. [Google Scholar] [CrossRef] [Green Version]
  38. Wang, Y.M.; Lu, P.J.; Ho, C.L.; Tsai, I.H. Characterization and molecular cloning of neurotoxic phospholipases A2 from Taiwan viper (Vipera russelli formosensis). Eur. J. Biochem. 1992, 209, 635–641. [Google Scholar] [CrossRef]
  39. Patikorn, C.; Ismail, A.K.; Abidin, S.A.Z.; Blanco, F.B.; Blessmann, J.; Choumlivong, K.; Comandante, J.D.; Doan, U.V.; Zainalabidin, M.I.; Khine, Y.Y.; et al. Situation of snakebite, antivenom market and access to antivenoms in ASEAN countries. BMJ Glob. Health 2022, 7, e007639. [Google Scholar] [CrossRef]
  40. Bulfone, T.C.; Samuel, S.P.; Bickler, P.E.; Lewin, M.R. Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite. J. Trop. Med. 2018, 2018, 4320175. [Google Scholar] [CrossRef] [Green Version]
  41. Ranawaka, U.K.; Lalloo, D.G.; de Silva, H.J. Neurotoxicity in Snakebite-The Limits of Our Knowledge. PLoS Negl. Trop. Dis. 2013, 7, e2302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Madhushani, U.; Isbister, G.K.; Tasoulis, T.; Hodgson, W.C.; Silva, A. In-Vitro Neutralization of the Neurotoxicity of Coastal Taipan Venom by Australian Polyvalent Antivenom: The Window of Opportunity. Toxins 2020, 12, 690. [Google Scholar] [CrossRef] [PubMed]
  43. Silva, A.; Maduwage, K.; Sedgwick, M.; Pilapitiya, S.; Weerawansa, P.; Dahanayaka, N.J.; Buckley, N.A.; Johnston, C.; Siribaddana, S.; Isbister, G.K. Neuromuscular Effects of Common Krait (Bungarus caeruleus) Envenoming in Sri Lanka. PLoS Negl. Trop. Dis. 2016, 10, e0004368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Wang, Y.; Zhang, J.; Zhang, D.; Xiao, H.; Xiong, S.; Huang, C. Exploration of the Inhibitory Potential of Varespladib for Snakebite Envenomation. Molecules 2018, 23, 391. [Google Scholar] [CrossRef]
  45. Lewin, M.; Samuel, S.; Merkel, J.; Bickler, P. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins 2016, 8, 248. [Google Scholar] [CrossRef] [Green Version]
  46. Xiao, H.; Li, H.; Zhang, D.; Li, Y.; Sun, S.; Huang, C. Inactivation of Venom PLA2 Alleviates Myonecrosis and Facilitates Muscle Regeneration in Envenomed Mice: A Time Course Observation. Molecules 2018, 23, 1911. [Google Scholar] [CrossRef] [Green Version]
  47. Bryan-Quirós, W.; Fernández, J.; Gutiérrez, J.M.; Lewin, M.R.; Lomonte, B. Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipase A2. Toxicon 2019, 157, 1–7. [Google Scholar] [CrossRef]
  48. Gutiérrez, J.M.; Lewin, M.R.; Williams, D.J.; Lomonte, B. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms. Toxins 2020, 12, 131. [Google Scholar] [CrossRef] [Green Version]
  49. Lewin, M.R.; Gutiérrez, J.M.; Samuel, S.P.; Herrera, M.; Bryan-Quirós, W.; Lomonte, B.; Bickler, P.E.; Bulfone, T.C.; Williams, D.J. Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom. Toxins 2018, 10, 380. [Google Scholar] [CrossRef] [Green Version]
  50. Madhushani, U.; Thakshila, P.; Hodgson, W.C.; Isbister, G.K.; Silva, A. Effect of Indian Polyvalent Antivenom in the Prevention and Reversal of Local Myotoxicity Induced by Common Cobra (Naja naja) Venom from Sri Lanka In Vitro. Toxins 2021, 13, 308. [Google Scholar] [CrossRef]
  51. Johnston, C.I.; Brown, S.G.A.; O’Leary, M.A.; Currie, B.J.; Greenberg, R.; Taylor, M.; Barnes, C.; White, J.; Isbister, G.K.; the ASP investigators. Mulga snake (Pseudechis australis) envenoming: A spectrum of myotoxicity, anticoagulant, coagulopathy, haemolysis and the role of early antivenom therapy—Australian Snakebite Project (ASP-19). Clin. Toxicol. 2013, 51, 417–424. [Google Scholar] [CrossRef] [PubMed]
  52. Johnston, C.I.; Ryan, N.M.; O’Leary, M.A.; Brown, S.G.A.; Isbister, G.K. Australian taipan (Oxyuranus spp.) envenoming: Clinical effects and potential benefits of early antivenom therapy—Australian Snakebite Project (ASP—25). Clin. Toxicol. 2017, 55, 115–122. [Google Scholar] [CrossRef] [PubMed]
  53. Gutiérrez, J.M.; Leon, G.; Lomonte, B. Pharmacokinetic-Pharmacodynamic Relationships of Immunoglobulin Therapy for Envenomation. Clin. Pharmacokinet. 2003, 42, 721–741. [Google Scholar] [CrossRef] [PubMed]
  54. Isbister, G.K.; Maduwage, K.; Saiao, A.; Buckley, N.A.; Jayamanne, S.F.; Seyed, S.; Mohamed, F.; Chathuranga, U.; Mendes, A.; Abeysinghe, C.; et al. Population Pharmacokinetics of an Indian F(ab’)2 Snake Antivenom in Patients with Russell’s Viper (Daboia russelii) Bites. PLoS Negl. Trop. Dis. 2015, 9, e0003873. [Google Scholar] [CrossRef] [PubMed]
  55. Riviére, G.; Choumet, V.; Saliou, B.; Debray, M.; Bon, C. Absorption and Elimination of Viper Venom after Antivenom Administration. J. Pharmacol. Exp. Ther 1998, 285, 490–495. [Google Scholar] [PubMed]
  56. Silva, A.; Isbister, G.K. Current research into snake antivenoms, their mechanisms of action and applications. Biochem. Soc. Trans. 2020, 48, 537–546. [Google Scholar] [CrossRef] [Green Version]
  57. Salvador, G.H.M.; Borges, R.J.; Lomonte, B.; Lewin, M.R.; Fontes, M.R.M. The synthetic varespladib molecule is a multi-functional inhibitor for PLA2 and PLA2-like ophidic toxins. Biochim Biophys Acta Gen. Subj. 2021, 1865, 129913. [Google Scholar] [CrossRef]
  58. Salvador, G.H.M.; Gomes, A.A.S.; Bryan-Quirós, W.; Fernández, J.; Lewin, M.R.; Gutiérrez, J.M.; Lomonte, B.; Fontes, M.R.M. Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920). Sci. Rep. 2019, 9, 17203. [Google Scholar] [CrossRef] [Green Version]
  59. Tan, C.H.; Lingam, T.M.C.; Tan, K.Y. Varespladib (LY315920) rescued mice from fatal neurotoxicity caused by venoms of five major Asiatic kraits (Bungarus spp.) in an experimental envenoming and rescue model. Acta Trop. 2022, 227, 106289. [Google Scholar] [CrossRef]
  60. Silva-Carvalho, R.; Gaspar, M.Z.; Quadros, L.H.B.; Lobo, L.G.G.; Rogério, L.M.; Santos, N.T.S.; Zerbinatti, M.C.; Santarém, C.L.; Silva, E.O.; Gerez, J.R.; et al. In Vivo Treatment with Varespladib, a Phospholipase A2 Inhibitor, Prevents the Peripheral Neurotoxicity and Systemic Disorders Induced by Micrurus Corallinus (Coral Snake) in Rats. Toxicol. Lett. 2022, 356, 54–63. [Google Scholar] [CrossRef]
  61. World Health Organization. Regional Action Plan for Prevention and Control of Snakebite Envenoming in the South-East Asia 2022–2030; Regional Office for South-East Asia, World Health Organization: New Delhi, India, 2022.
Toxins 15 00062 g001 550
Figure 1. Effect of post-venom addition of antivenom (AV; 15 µL) on venom (10 µg/mL) induced pre-synaptic neurotoxicity in the chick biventer cervicis nerve-muscle preparation. Effect of AV added (a) 30 or (b) 60 min after venom on indirect twitch inhibition. Arrows indicate the times of addition of AV; n = 5–6; * p < 0.05, significantly different from vehicle control at corresponding time point; # p < 0.05, significantly different from venom alone at corresponding time point, one-way ANOVA followed by Bonferroni’s post hoc test. Effect of (c) vehicle, venom alone or AV added either 30 min or 60 min after venom on responses to exogenous agonists; ACh (1 mM), CCh (20 µM) and KCl (40 mM). n = 11–12, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 1. Effect of post-venom addition of antivenom (AV; 15 µL) on venom (10 µg/mL) induced pre-synaptic neurotoxicity in the chick biventer cervicis nerve-muscle preparation. Effect of AV added (a) 30 or (b) 60 min after venom on indirect twitch inhibition. Arrows indicate the times of addition of AV; n = 5–6; * p < 0.05, significantly different from vehicle control at corresponding time point; # p < 0.05, significantly different from venom alone at corresponding time point, one-way ANOVA followed by Bonferroni’s post hoc test. Effect of (c) vehicle, venom alone or AV added either 30 min or 60 min after venom on responses to exogenous agonists; ACh (1 mM), CCh (20 µM) and KCl (40 mM). n = 11–12, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g001
Toxins 15 00062 g002 550
Figure 2. Effect of post-venom addition of antivenom (AV; 20 µL) on venom (10 µg/mL) induced myotoxicity in the chick biventer cervicis nerve-muscle preparation. Effect of AV added (a) 30 or (c) 60 min after venom on direct twitch inhibition. Arrows indicate the times of addition of AV; * p < 0.05, significantly different from vehicle control at corresponding time point. Effect of AV added at (b) 30 or (d) 60 min after venom on baseline tension, where * p < 0.05, significantly different from vehicle response, all one-way ANOVA followed by Bonferroni’s post hoc test. n = 4–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 2. Effect of post-venom addition of antivenom (AV; 20 µL) on venom (10 µg/mL) induced myotoxicity in the chick biventer cervicis nerve-muscle preparation. Effect of AV added (a) 30 or (c) 60 min after venom on direct twitch inhibition. Arrows indicate the times of addition of AV; * p < 0.05, significantly different from vehicle control at corresponding time point. Effect of AV added at (b) 30 or (d) 60 min after venom on baseline tension, where * p < 0.05, significantly different from vehicle response, all one-way ANOVA followed by Bonferroni’s post hoc test. n = 4–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g002
Toxins 15 00062 g003 550
Figure 3. Effect of venom (10 µg/mL) in the presence or absence of Varespladib (0.8 µM or 26 µM) on (a) indirect (nerve-mediated) twitches and (b) contractile responses to exogenous agonists ACh (1 mM), CCh (20 µM) and KCl (40 mM) in the chick biventer cervicis nerve-muscle preparation. (a) Protective effect of Varespladib on venom-induced pre-synaptic neurotoxicity; * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib, two-way ANOVA followed by Tukey’s post hoc test. (b) Effect of Varespladib on responses to exogenous agonists; * p < 0.05, significantly different from pre-venom response to the same agonists, student’s paired t-test; # p < 0.05, significantly different from venom alone, two-way ANOVA, followed by Tukey’s post hoc test, n = 5–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 3. Effect of venom (10 µg/mL) in the presence or absence of Varespladib (0.8 µM or 26 µM) on (a) indirect (nerve-mediated) twitches and (b) contractile responses to exogenous agonists ACh (1 mM), CCh (20 µM) and KCl (40 mM) in the chick biventer cervicis nerve-muscle preparation. (a) Protective effect of Varespladib on venom-induced pre-synaptic neurotoxicity; * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib, two-way ANOVA followed by Tukey’s post hoc test. (b) Effect of Varespladib on responses to exogenous agonists; * p < 0.05, significantly different from pre-venom response to the same agonists, student’s paired t-test; # p < 0.05, significantly different from venom alone, two-way ANOVA, followed by Tukey’s post hoc test, n = 5–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g003
Toxins 15 00062 g004 550
Figure 4. Effect of Chinese D. siamensis (10 µg/mL) venom in the presence or absence of Varespladib (0.8 or 26 µM) on (a) direct twitches and (b) baseline tension in the chick biventer cervicis nerve-muscle preparation. (a) Protective effect of Varespladib against venom-induced myotoxicity; * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib; + p < 0.05, significantly different from venom + Var 26 µM; two-way ANOVA followed by Tukey’s post hoc test. (b) Effect of Varespladib on venom-induced increases in baseline tension; * p < 0.05, significantly different from Varespladib alone; two-way ANOVA followed by Tukey’s post hoc test; # p < 0.05, significantly different to venom in the absence of Varespladib n = 5–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 4. Effect of Chinese D. siamensis (10 µg/mL) venom in the presence or absence of Varespladib (0.8 or 26 µM) on (a) direct twitches and (b) baseline tension in the chick biventer cervicis nerve-muscle preparation. (a) Protective effect of Varespladib against venom-induced myotoxicity; * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib; + p < 0.05, significantly different from venom + Var 26 µM; two-way ANOVA followed by Tukey’s post hoc test. (b) Effect of Varespladib on venom-induced increases in baseline tension; * p < 0.05, significantly different from Varespladib alone; two-way ANOVA followed by Tukey’s post hoc test; # p < 0.05, significantly different to venom in the absence of Varespladib n = 5–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g004
Toxins 15 00062 g005 550
Figure 5. Effect of the addition of Varespladib (0.8 or 26 µM), 60 min post venom, on venom-induced pre-synaptic neurotoxicity (indirect twitches) in the chick biventer cervicis nerve-muscle preparation. * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib; two-way ANOVA followed by Tukey’s post hoc test. n = 5–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 5. Effect of the addition of Varespladib (0.8 or 26 µM), 60 min post venom, on venom-induced pre-synaptic neurotoxicity (indirect twitches) in the chick biventer cervicis nerve-muscle preparation. * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib; two-way ANOVA followed by Tukey’s post hoc test. n = 5–6, where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g005
Toxins 15 00062 g006 550
Figure 6. Effect of the addition of Varespladib (0.8 or 26 µM), 60 min post venom, on venom-induced myotoxicity. Arrows indicate the time of addition of Varespladib. (a) Effect of Varespladib on direct twitch reduction induced by venom; * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom alone, two-way ANOVA followed by Tukey’s post hoc test. (b) Effect of Varespladib on venom-induced increases of baseline tension; * p < 0.05, significantly different from Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib, two-way ANOVA followed by Tukey’s post hoc. n = 4–6 where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 6. Effect of the addition of Varespladib (0.8 or 26 µM), 60 min post venom, on venom-induced myotoxicity. Arrows indicate the time of addition of Varespladib. (a) Effect of Varespladib on direct twitch reduction induced by venom; * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom alone, two-way ANOVA followed by Tukey’s post hoc test. (b) Effect of Varespladib on venom-induced increases of baseline tension; * p < 0.05, significantly different from Varespladib alone; # p < 0.05, significantly different to venom in the absence of Varespladib, two-way ANOVA followed by Tukey’s post hoc. n = 4–6 where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g006
Toxins 15 00062 g007 550
Figure 7. Effect of the addition of antivenom (AV; 15 µL) and Varespladib (0.8 µM), 60 min post venom, on the pre-synaptic neurotoxic effects of venom (10 µg/mL). Arrows indicate the time of addition of combined treatment. * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of treatment, one-way ANOVA followed by Bonferroni’s post hoc test. n = 4–6 where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 7. Effect of the addition of antivenom (AV; 15 µL) and Varespladib (0.8 µM), 60 min post venom, on the pre-synaptic neurotoxic effects of venom (10 µg/mL). Arrows indicate the time of addition of combined treatment. * p < 0.05, significantly different to Varespladib alone; # p < 0.05, significantly different to venom in the absence of treatment, one-way ANOVA followed by Bonferroni’s post hoc test. n = 4–6 where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g007
Toxins 15 00062 g008 550
Figure 8. Effect of the addition of antivenom (AV; 20 µL) and Varespladib (0.8 µM), 60 min post venom, on the myotoxic effects of venom (10 µg/mL). Arrows indicate the time of addition of combined treatment. (a) Effect on direct twitches; * p < 0.05, significantly different to Varespladib alone; one-way ANOVA followed by Bonferroni’s post hoc test. (b) Effect on baseline tension; * p < 0.05, significantly different from vehicle response; # p < 0.05, significantly different from venom alone; all one-way ANOVA followed by Bonferroni’s post hoc test. n = 4–6 where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Figure 8. Effect of the addition of antivenom (AV; 20 µL) and Varespladib (0.8 µM), 60 min post venom, on the myotoxic effects of venom (10 µg/mL). Arrows indicate the time of addition of combined treatment. (a) Effect on direct twitches; * p < 0.05, significantly different to Varespladib alone; one-way ANOVA followed by Bonferroni’s post hoc test. (b) Effect on baseline tension; * p < 0.05, significantly different from vehicle response; # p < 0.05, significantly different from venom alone; all one-way ANOVA followed by Bonferroni’s post hoc test. n = 4–6 where n is the number of preparations from different animals; error bars indicate standard error of the mean.
Toxins 15 00062 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lay, M.; Liang, Q.; Isbister, G.K.; Hodgson, W.C. In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell’s Viper (Daboia siamensis) Venom Toxicity. Toxins 2023, 15, 62. https://doi.org/10.3390/toxins15010062

AMA Style

Lay M, Liang Q, Isbister GK, Hodgson WC. In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell’s Viper (Daboia siamensis) Venom Toxicity. Toxins. 2023; 15(1):62. https://doi.org/10.3390/toxins15010062

Chicago/Turabian Style

Lay, Mimi, Qing Liang, Geoffrey K. Isbister, and Wayne C. Hodgson. 2023. "In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell’s Viper (Daboia siamensis) Venom Toxicity" Toxins 15, no. 1: 62. https://doi.org/10.3390/toxins15010062

APA Style

Lay, M., Liang, Q., Isbister, G. K., & Hodgson, W. C. (2023). In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell’s Viper (Daboia siamensis) Venom Toxicity. Toxins, 15(1), 62. https://doi.org/10.3390/toxins15010062

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop